

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the management of pediatric... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2635/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2635" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the management of pediatric acute lymphoblastic leukemia" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the management of pediatric acute lymphoblastic leukemia.">
            <meta name="og:description" content="Read the latest article version by Jan Star&yacute;, Ond&#345;ej Hru&scaron;&aacute;k, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10285">
            <meta name="article-id" content="9548">
            <meta name="dc.title" content="Recent advances in the management of pediatric acute lymphoblastic leukemia">
            <meta name="dc.description" content="Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite enormous improvement of prognosis during the last half century, ALL remains a major cause of childhood cancer-related mortality. During the past decade, whole genomic methods have enhanced our knowledge of disease biology. Stratification of therapy according to early treatment response measured by minimal residual disease allows risk group assignment into different treatment arms, ranging from reduction to intensification of treatment. Progress has been achieved in academic clinical trials by optimization of combined chemotherapy, which continues to be the mainstay of contemporary treatment. The availability of suitable volunteer main histocompatibility antigen-matched unrelated donors has increased the rates of hematopoietic stem cell transplantation (HSCT) over the past two decades. Allogeneic HSCT has become an alternative treatment for selected, very-high-risk patients. However, intensive treatment burdens children with severe acute toxic effects that can cause permanent organ damage and even toxic death. Immunotherapeutic approaches have recently come to the forefront in ALL therapy. Monoclonal antibodies blinatumomab and inotuzumab ozogamicin as well as gene-modified T cells directed to specific target antigens have shown efficacy against resistant/relapsed leukemia in phase I/II studies. Integration of these newer modalities into combined regimens with chemotherapy may rescue a subset of children not curable by contemporary therapy. Another major challenge will be to incorporate less toxic regimens into the therapy of patients with low-risk disease who have a nearly 100% chance of being cured, and the ultimate goal is to improve their quality of life while maintaining a high cure rate.">
            <meta name="dc.subject" content="paediatric, leukaemia, ALL, HSCT, immunotherapy, monoclonal antibodies">
            <meta name="dc.creator" content="Star&yacute;, Jan">
            <meta name="dc.creator" content="Hru&scaron;&aacute;k, Ond&#345;ej">
            <meta name="dc.date" content="2016/11/04">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9548.1">
            <meta name="dc.source" content="F1000Research 2016 5:2635">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="paediatric">
            <meta name="prism.keyword" content="leukaemia">
            <meta name="prism.keyword" content="ALL">
            <meta name="prism.keyword" content="HSCT">
            <meta name="prism.keyword" content="immunotherapy">
            <meta name="prism.keyword" content="monoclonal antibodies">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/11/04">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2635">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9548.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2635">
            <meta name="citation_title" content="Recent advances in the management of pediatric acute lymphoblastic leukemia">
            <meta name="citation_abstract" content="Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite enormous improvement of prognosis during the last half century, ALL remains a major cause of childhood cancer-related mortality. During the past decade, whole genomic methods have enhanced our knowledge of disease biology. Stratification of therapy according to early treatment response measured by minimal residual disease allows risk group assignment into different treatment arms, ranging from reduction to intensification of treatment. Progress has been achieved in academic clinical trials by optimization of combined chemotherapy, which continues to be the mainstay of contemporary treatment. The availability of suitable volunteer main histocompatibility antigen-matched unrelated donors has increased the rates of hematopoietic stem cell transplantation (HSCT) over the past two decades. Allogeneic HSCT has become an alternative treatment for selected, very-high-risk patients. However, intensive treatment burdens children with severe acute toxic effects that can cause permanent organ damage and even toxic death. Immunotherapeutic approaches have recently come to the forefront in ALL therapy. Monoclonal antibodies blinatumomab and inotuzumab ozogamicin as well as gene-modified T cells directed to specific target antigens have shown efficacy against resistant/relapsed leukemia in phase I/II studies. Integration of these newer modalities into combined regimens with chemotherapy may rescue a subset of children not curable by contemporary therapy. Another major challenge will be to incorporate less toxic regimens into the therapy of patients with low-risk disease who have a nearly 100% chance of being cured, and the ultimate goal is to improve their quality of life while maintaining a high cure rate.">
            <meta name="citation_description" content="Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite enormous improvement of prognosis during the last half century, ALL remains a major cause of childhood cancer-related mortality. During the past decade, whole genomic methods have enhanced our knowledge of disease biology. Stratification of therapy according to early treatment response measured by minimal residual disease allows risk group assignment into different treatment arms, ranging from reduction to intensification of treatment. Progress has been achieved in academic clinical trials by optimization of combined chemotherapy, which continues to be the mainstay of contemporary treatment. The availability of suitable volunteer main histocompatibility antigen-matched unrelated donors has increased the rates of hematopoietic stem cell transplantation (HSCT) over the past two decades. Allogeneic HSCT has become an alternative treatment for selected, very-high-risk patients. However, intensive treatment burdens children with severe acute toxic effects that can cause permanent organ damage and even toxic death. Immunotherapeutic approaches have recently come to the forefront in ALL therapy. Monoclonal antibodies blinatumomab and inotuzumab ozogamicin as well as gene-modified T cells directed to specific target antigens have shown efficacy against resistant/relapsed leukemia in phase I/II studies. Integration of these newer modalities into combined regimens with chemotherapy may rescue a subset of children not curable by contemporary therapy. Another major challenge will be to incorporate less toxic regimens into the therapy of patients with low-risk disease who have a nearly 100% chance of being cured, and the ultimate goal is to improve their quality of life while maintaining a high cure rate.">
            <meta name="citation_keywords" content="paediatric, leukaemia, ALL, HSCT, immunotherapy, monoclonal antibodies">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jan Star&yacute;">
            <meta name="citation_author_institution" content="Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic">
            <meta name="citation_author" content="Ond&#345;ej Hru&scaron;&aacute;k">
            <meta name="citation_author_institution" content="Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic">
            <meta name="citation_publication_date" content="2016/11/04">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2635">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9548.1">
            <meta name="citation_firstpage" content="2635">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2635/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2635.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10285 /> <input type=hidden id=articleId name=articleId value=9548 /> <input type=hidden id=xmlUrl value="/articles/5-2635/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2635-v1.xml"> <input type=hidden id=article_uuid value=faf62d79-ce36-4f23-9cf8-1a8a3144742d /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the management of pediatric acute lymphoblastic leukemia"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9548.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9548.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2635"
  },
  "headline": "Recent advances in the management of pediatric acute lymphoblastic leukemia",
  "datePublished": "2016-11-04T16:31:19",
  "dateModified": "2016-11-04T16:31:19",
  "author": [
    {
      "@type": "Person",
      "name": "Jan Star&yacute;"
    },    {
      "@type": "Person",
      "name": "Ond&#345;ej Hru&scaron;&aacute;k"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite enormous improvement of prognosis during the last half century, ALL remains a major cause of childhood cancer-related mortality. During the past decade, whole genomic methods have enhanced our knowledge of disease biology. Stratification of therapy according to early treatment response measured by minimal residual disease allows risk group assignment into different treatment arms, ranging from reduction to intensification of treatment. Progress has been achieved in academic clinical trials by optimization of combined chemotherapy, which continues to be the mainstay of contemporary treatment. The availability of suitable volunteer main histocompatibility antigen-matched unrelated donors has increased the rates of hematopoietic stem cell transplantation (HSCT) over the past two decades. Allogeneic HSCT has become an alternative treatment for selected, very-high-risk patients. However, intensive treatment burdens children with severe acute toxic effects that can cause permanent organ damage and even toxic death. Immunotherapeutic approaches have recently come to the forefront in ALL therapy. Monoclonal antibodies blinatumomab and inotuzumab ozogamicin as well as gene-modified T cells directed to specific target antigens have shown efficacy against resistant/relapsed leukemia in phase I/II studies. Integration of these newer modalities into combined regimens with chemotherapy may rescue a subset of children not curable by contemporary therapy. Another major challenge will be to incorporate less toxic regimens into the therapy of patients with low-risk disease who have a nearly 100% chance of being cured, and the ultimate goal is to improve their quality of life while maintaining a high cure rate."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2635/v1",
            "name": "Recent advances in the management of pediatric acute lymphoblastic..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the management of pediatric acute lymphoblastic... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10285 data-id=9548 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9548.1" data-recommended="" data-doi="10.12688/f1000research.9548.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2635/v1/pdf?article_uuid=faf62d79-ce36-4f23-9cf8-1a8a3144742d" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9548-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9548-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9548-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Starý J and Hrušák O. Recent advances in the management of pediatric acute lymphoblastic leukemia [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2635 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9548.1" target=_blank>https://doi.org/10.12688/f1000research.9548.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9548-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9548 id=track-article-signin-9548 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9548?target=/articles/5-2635/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10285 /> <input name=articleId type=hidden value=9548 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the management of pediatric acute lymphoblastic leukemia</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:jan.stary@lfmotol.cuni.cz" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jan Star&yacute;</span></a><a href="https://orcid.org/0000-0002-6818-7743" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6818-7743</div>,&nbsp;</span><span class="">Ond&#345;ej Hru&scaron;&aacute;k</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:jan.stary@lfmotol.cuni.cz" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jan Star&yacute;</span></a><a href="http://orcid.org/0000-0002-6818-7743" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6818-7743</div>,&nbsp;</span><span class="">Ond&#345;ej Hru&scaron;&aacute;k</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 04 Nov 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9548.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=17900-17299></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=2998-17298></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite enormous improvement of prognosis during the last half century, ALL remains a major cause of childhood cancer-related mortality. During the past decade, whole genomic methods have enhanced our knowledge of disease biology. Stratification of therapy according to early treatment response measured by minimal residual disease allows risk group assignment into different treatment arms, ranging from reduction to intensification of treatment. Progress has been achieved in academic clinical trials by optimization of combined chemotherapy, which continues to be the mainstay of contemporary treatment. The availability of suitable volunteer main histocompatibility antigen-matched unrelated donors has increased the rates of hematopoietic stem cell transplantation (HSCT) over the past two decades. Allogeneic HSCT has become an alternative treatment for selected, very-high-risk patients. However, intensive treatment burdens children with severe acute toxic effects that can cause permanent organ damage and even toxic death. Immunotherapeutic approaches have recently come to the forefront in ALL therapy. Monoclonal antibodies blinatumomab and inotuzumab ozogamicin as well as gene-modified T cells directed to specific target antigens have shown efficacy against resistant/relapsed leukemia in phase I/II studies. Integration of these newer modalities into combined regimens with chemotherapy may rescue a subset of children not curable by contemporary therapy. Another major challenge will be to incorporate less toxic regimens into the therapy of patients with low-risk disease who have a nearly 100% chance of being cured, and the ultimate goal is to improve their quality of life while maintaining a high cure rate. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> paediatric, leukaemia, ALL, HSCT, immunotherapy, monoclonal antibodies </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Jan Star&yacute; (<a href="mailto:jan.stary@lfmotol.cuni.cz">jan.stary@lfmotol.cuni.cz</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Jan Starý </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Supported by the project (Ministry of Health) for conceptual development of research organization 0006420 (University Hospital Motol, Prague, Czech Republic). <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Starý J and Hrušák O. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Starý J and Hrušák O. Recent advances in the management of pediatric acute lymphoblastic leukemia [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2635 (<a href="https://doi.org/10.12688/f1000research.9548.1" target=_blank>https://doi.org/10.12688/f1000research.9548.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 04 Nov 2016, <b>5</b>(F1000 Faculty Rev):2635 (<a href="https://doi.org/10.12688/f1000research.9548.1" target=_blank>https://doi.org/10.12688/f1000research.9548.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 04 Nov 2016, <b>5</b>(F1000 Faculty Rev):2635 (<a href="https://doi.org/10.12688/f1000research.9548.1" target=_blank>https://doi.org/10.12688/f1000research.9548.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e155>Introduction</h2><p class="" id=d30476e158>Acute lymphoblastic leukemia (ALL) accounts for 25% of all childhood cancers and its outcome significantly influences the overall treatment results in pediatric oncology. The improvement of prognosis in childhood ALL is one of the most successful stories of modern medicine. An almost uniformly fatal disease at the beginning of the 1960s has transformed into a curable disorder in more than 90% of children with contemporary therapy. The major reason for improved survival is a decreased risk of relapse<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The outcome continues to improve at the beginning of the 21st century. Moreover, this progress takes place not only in high-income countries but also in countries with limited resources because conventional chemotherapy is inexpensive and readily available worldwide<sup><a href="#ref-3">3</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e175>Early response to treatment</h2><p class="" id=d30476e178>Since the beginning of the 2000s, patients have been stratified into risk groups according to the early treatment response evaluated by minimal residual disease (MRD). It has been determined by detection of aberrant leukemic phenotype by flow cytometry or by specific rearrangements of immunoreceptor genes <i>IgH</i>/<i>TCR</i> (heavy immunoglobulin/T-cell receptor)<sup><a href="#ref-4">4</a></sup>. MRD has been confirmed in multivariate analysis as the most significant prognostic factor within all immunophenotypes and genetic subgroups. MRD is first monitored during and at the end of induction<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Patients with a slow early response are stratified into the high-risk group. They profit from a more intensive post-induction treatment and augmented delayed intensification<sup><a href="#ref-7">7</a>–<a href="#ref-10">10</a></sup>. Rapid early responders to combined chemotherapy with B-cell precursor (BCP)-ALL benefit from early intensification of post-induction therapy, not from a prolonged double-delayed (augmented) intensification<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. MRD performed about 3 months from diagnosis—that is, after early post-induction treatment—identifies a subset of patients with inferior outcome on Berlin-Frankfurt-Münster (BFM) protocols<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Treatment of T-cell (T)-ALL stratified according to treatment response has led to the excellent event-free survival (EFS) and overall survival (OS) of 85% and over 90%, respectively<sup><a href="#ref-15">15</a></sup>, although T-cell immunophenotype remains an adverse risk factor in multivariate analyses of clinical trials<sup><a href="#ref-1">1</a>,<a href="#ref-14">14</a></sup>. Stratification according to MRD response helps to improve prognosis of T-ALL patients in general but also in subsets, such as in the recently identified early T-cell precursor (ETP)-ALL. ETP-ALL patients tend to respond more slowly to induction therapy, and initial studies reported poor outcome<sup><a href="#ref-16">16</a></sup>. When stratified according to MRD response, their outcome is comparable to those with non-ETP-ALL<sup><a href="#ref-15">15</a>,<a href="#ref-17">17</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e245>Contemporary therapy</h2><p class="" id=d30476e248>Optimization of standard chemotherapy in academic randomized clinical studies improves the outcome even at the beginning of the 21st century. Substituting dexamethasone for prednisone for 3 weeks in the context of 2 years of BFM multi-agent therapy reduced the relapse risk by one-third<sup><a href="#ref-18">18</a></sup>. On the other hand, dexamethasone also accounts for both long- and short-term side effects, many of which are dependent on dose intensity<sup><a href="#ref-19">19</a></sup>. The immunosuppressive action of dexamethasone, alongside the use of anthracyclines, contributed to higher incidence of infection-related mortality compared with prednisone and thus resulted in no difference in OS between both arms. High-dose methotrexate 5 g/m<sup>2</sup> (HD MTX) in consolidation reduces bone marrow (BM) and extramedullary relapses more efficiently than lower escalating doses of intravenous MTX without leucovorin rescue (followed by <span style="font-variant: small-caps">l</span>-asparaginase, Capizzi regimen) in BCP-ALL<sup><a href="#ref-20">20</a></sup>. <span style="font-variant: small-caps">l</span>-asparaginase has been a key component of all treatment regimens for childhood ALL since the 1960s. Its optimal dose, preparation, and route of administration remain uncertain<sup><a href="#ref-21">21</a></sup>. Prolonged and intensified therapy with <span style="font-variant: small-caps">l</span>-asparaginase improves the outcome of children with ALL. Administration of <span style="font-variant: small-caps">l</span>-asparaginase can be hampered by allergic reactions. Clinical allergy is associated with inactivation of <span style="font-variant: small-caps">l</span>-asparaginase by antibodies. Apart from overt allergy, antibodies can also cause a so-called silent inactivation, in which <span style="font-variant: small-caps">l</span>-asparaginase is neutralized subclinically. Monitoring of <span style="font-variant: small-caps">l</span>-asparaginase blood levels is useful because it detects silent inactivation<sup><a href="#ref-22">22</a></sup>. Pegylated <i>Escherichia coli</i> <span style="font-variant: small-caps">l</span>-asparaginase (<span style="font-variant: small-caps">l</span>-asparaginase coupled to polyethylene glycol) has a longer half-life and is potentially less immunogenic than native <i>E. coli</i> <span style="font-variant: small-caps">l</span>-asparaginase and has been used with increasing frequency in frontline pediatric treatment regimens<sup><a href="#ref-23">23</a></sup>. Following allergy to pegylated <span style="font-variant: small-caps">l</span>-asparaginase, Erwinia <span style="font-variant: small-caps">l</span>-asparaginase can be substituted and achieves therapeutic activity<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d30476e327>Cranial irradiation is associated with a higher incidence of secondary malignancies and cognitive impairment in young children<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. The use of dexamethasone, HD MTX, and intrathecal triple therapy in central nervous system (CNS) leukemia treatment has enabled reduction or even omission of cranial irradiation without compromising OS<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. In a recently published meta-analysis, cranial radiotherapy (CRT) was associated with reduced risk of relapse only in patients with overt CNS leukemia at diagnosis<sup><a href="#ref-29">29</a></sup>. Omission of CRT from childhood ALL therapy results in improved cognitive outcome. However, despite this improvement, survivors continue to demonstrate the elevated risk for attention deficits when compared with a reference population of children<sup><a href="#ref-30">30</a></sup>.</p><p class="" id=d30476e352>The indication of hematopoietic stem cell transplantation (HSCT) in first complete remission (CR) is recommended for a subgroup of children (approximately 5%) who are resistant to current chemotherapy (induction failure, persistent high MRD)<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>.</p><p class="" id=d30476e362>Maintenance treatment with mercaptopurine and MTX is an integral part of ALL treatment. Lower adherence to oral mercaptopurine increases relapse risk<sup><a href="#ref-33">33</a></sup>. The addition of vincristine plus steroid pulses in maintenance treatment still may be useful in cases where less intensive early therapy is used<sup><a href="#ref-34">34</a></sup>. Children with intermediate-risk ALL who received intensive chemotherapy on the basis of BFM protocols did not benefit from intensification of the maintenance therapy with pulses of vincristine and dexamethasone<sup><a href="#ref-35">35</a></sup>. Some subgroups of patients with unfavorable biology, like deletion of the gene for transcription factor <i>IKZF1</i>, might benefit from pulses during maintenance even on treatment with BFM backbone<sup><a href="#ref-36">36</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e387>Treatment-related mortality</h2><p class="" id=d30476e390>The incidence of treatment-related mortality (TRM) on contemporary ALL trials is reported to be between 2 and 4%. The most common cause of death is infection. The 5-year EFS of children with low-risk ALL who have favorable cytogenetics and good response to treatment is higher than 90%, and death from TRM is as common as relapse. As such, reducing infection-related mortality is a paramount concern when improving outcomes in childhood ALL. Patients at highest risk of infection-related TRM are children older than 10 years, slow early responders, and those with Down syndrome (DS)<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. Lower socioeconomic status, non-compliance to therapy, and (in countries with limited resources) malnutrition all increase the risk of treatment failure<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e410>Biologic and genetic features: targeted therapy</h2><p class="" id=d30476e413>Good risk prognostic genetic biomarkers of BCP-ALL are t(12;21) (ETV6-RUNX1) and high hyperdiploidy (51–65 chromosomes)<sup><a href="#ref-41">41</a></sup>. Patients with either of these abnormalities have a 5-year OS of over 90%. Five chromosomal abnormalities—MLL (KMT2A) translocations, t(9;22) (BCR-ABL1), t(17;19) (TCF3-HLF), near haploidy (fewer than 30 chromosomes), and low hypodiploidy (30–39 chromosomes)—are well-recognized prognostic biomarkers of high-risk disease at all ages<sup><a href="#ref-42">42</a></sup>. Previously reported uniformly poor outcome of patients with hypodiploidy of less than 45 chromosomes might be improved by MRD-stratified treatment<sup><a href="#ref-43">43</a></sup>. Approximately 30% of pediatric patients with BCP-ALL are screened negative for established diagnostic and prognostic markers. They are referred to as B-other ALL. Approximately 50% of B-other cases have a gene expression profile similar to that of BCR-ABL1-positive ALL. These cases form a subgroup that has been termed BCR-ABL1-like or Ph-like<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. They frequently harbor alterations of <i>IKZF1</i> or other B-lymphoid transcription factor genes. Stratification of these patients according to MRD helps to improve previously reported poor outcome of this subgroup<sup><a href="#ref-46">46</a></sup>. Kinase-activating gene fusions detected in this subgroup are collectively found in 1 to 2% of BCP-ALL cases and can be targeted with tyrosine kinase inhibitors (TKIs)<sup><a href="#ref-47">47</a></sup>. Patients failing initial treatment might profit from the introduction of TKIs to high-risk chemotherapy. Up to 5% of childhood ALL cases have JAK-STAT signaling pathway-activating fusions (<i>CRLF2</i>, <i>JAK2</i>, and <i>EPOR</i>), which appear to be targetable by JAK inhibitors<sup><a href="#ref-48">48</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e464>Philadelphia chromosome-positive acute lymphoblastic leukemia</h2><p class="" id=d30476e467>HSCT has been the gold standard treatment for maintaining CR in Philadelphia chromosome-positive (Ph<sup>+</sup>) ALL since the 1990s; however, its importance may change in the era of TKIs. The onset of targeted therapy exemplified by TKIs has revolutionized the therapy of Ph<sup>+</sup> ALL. TKIs are introduced early in induction and continue through maintenance treatment. Length of treatment and cumulative dose of TKIs seems to play a role in the achievement of a better outcome<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. MRD is considered to be essential for risk group stratification. Discrepancies in MRD using <i>IgH/TCR</i> and BCR-ABL1 fusion indicate that lineages other than BCP may also be affected by the disease<sup><a href="#ref-51">51</a></sup>. The best way to incorporate TKIs, conventional chemotherapy, and HSCT is still unclear. With current approaches, which are developed from high-risk protocols, acute toxicity is a significant problem. Future trials will examine the necessary chemotherapy dose intensity alongside TKI therapy and address in which subgroups HSCT is needed; with regard to TKIs, which agent to use, how long application should be, and what the role of post-HSCT is must be further investigated<sup><a href="#ref-52">52</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e498>Clinical features: age and Down syndrome</h2><p class="" id=d30476e501>Most of the adolescents older than 15 years can be cured with risk-adjusted intensive therapy without HSCT. They show higher rates of severe infections, osteonecrosis, thrombosis, and hyperglycemia<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. On the other hand, the outcome of infants younger than 1 year old is not improving. MLL gene rearrangement, which is associated with chemoresistance to conventional chemotherapy, is present in 80% of them. Their leukemic cells display a global hypermethylated genomic state. It explains remarkable sensitivity to demethylating agents<sup><a href="#ref-55">55</a></sup>. Their potential to improve the outcome of the infant ALL cases will be verified in clinical trials.</p><p class="" id=d30476e515>Children with DS-ALL have a higher cumulative incidence of relapses and therapy-related mortality (infectious deaths) than non-DS patients. They have low incidence of prognostically advantageous genetic subtypes (ETV6-RUNX1 fusion, hyperdiploidy 51–65 chromosomes). Higher risk of toxic complications puts pressure on physicians to reduce the treatment intensity in DS-ALL. However, even in DS, unmodified risk-adjusted ALL treatment, combined with good supportive care, is indicated<sup><a href="#ref-56">56</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e525>Leukemias of ambiguous lineage</h2><p class="" id=d30476e528>Up to 5% of acute leukemia cases present with some kind of lineage ambiguity. Among the four subsets of ambiguous lineage leukemias, the most prevalent are those classified by the presence of too many phenotype features of the opposite lineage (ALL versus acute myeloid leukemia). The existing definitions are arbitrary and sometimes are criticized for including too few markers (the World Health Organization definition, now most widely used) or too many markers (the previous EGIL—European Group for the Immunological Classification of Leukemias—definition)<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>. Irrespective of the definition, the prognosis of children with this type of ambiguity was slightly poorer when compared with other cases receiving the same treatment<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. Much rarer subtypes are bilineal (biclonal) leukemias, in which two or more clones belonging to different lineages coexist at diagnosis. Interestingly, emerging studies show that despite phenotypic differences, the two clones often share genetic features (<a href="#ref-61">61</a> and Thomas Alexander, personal communication). A third subtype, also uncommon, is the undifferentiated leukemia. Patients with this subset do not fulfill the existing criteria for ALL or for acute myeloid leukemia. In such situations, infiltration of hematopoietic organs by another malignancy should always be considered. The fourth subtype is represented by leukemias that change their phenotype from one lineage to another during the beginning of treatment. Historically, this feature has mostly been referred to as being associated with MLL rearrangements or BCR/ABL1<sup><a href="#ref-62">62</a></sup>. More recently, lineage switching toward monocytic lineage has been described mostly in ALLs with aberrant CD2 at presentation<sup><a href="#ref-63">63</a></sup>. This phenomenon is present in varying degrees in up to 4% of BCP-ALL cases and is mostly temporary, not requiring major changes of treatment; however, monocytosis as well as monocytoid organ infiltration may be clinically significant, and development into monocytic leukemia has been observed in one case<sup><a href="#ref-63">63</a></sup>. Besides CD2, such “swALL” cases are associated with changes in CEBPA methylation<sup><a href="#ref-63">63</a></sup> and overlap with ERG-deleted ALLs<sup><a href="#ref-64">64</a></sup>. Overall, owing to their rarity, ambiguous lineage leukemias should be studied cooperatively. An international study currently taking place addresses the treatment outcome of over 270 cases and their molecular background and aims to find the causal factors as well as optimal treatments<sup><a href="#ref-65">65</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e576>Relapsed acute lymphoblastic leukemia</h2><p class="" id=d30476e579>Relapse is diagnosed in fewer than 15% of children. Relapsed disease tends to be more drug resistant than is newly diagnosed ALL, as shown by lower disease clearance and reduced CR rate, especially in early relapses<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. When diagnosed, most ALL cases are oligoclonal. A patient’s sensitivity or resistance to therapy is affected by genetic variations in individual subclones, and these can influence a subsequent clonal evolution during treatment as well<sup><a href="#ref-68">68</a></sup>. Major diagnostic clone at diagnosis is eradicated by chemotherapy in the majority of cases. A substantial part of relapsed ALL cases arise from minor subclones already present at diagnosis. Some abnormalities gained under chemotherapy pressure confer resistance to important components of combined chemotherapy, like nucleoside analogues (<i>NT5C2</i>, <i>PRPS1</i> mutations) and glucocorticoids (<i>CREBBP</i> mutation)<sup><a href="#ref-69">69</a>–<a href="#ref-72">72</a></sup>. Despite this, the optimization of combined chemotherapy might improve the outcome. The UK ALL R3 randomized trial for patients in first relapse compared two anthracyclines, mitoxantrone and idarubicin, in induction. Relapse incidence was significantly lower in the group treated with mitoxantrone and translated into a clear survival advantage of more than 20%, one of the largest improvements ever achieved by a single drug. Surprisingly, no difference in MRD could be detected between two randomized groups. Three-year OS was 69% in the mitoxantrone group<sup><a href="#ref-73">73</a></sup>. The most frequent type of relapse is late BM relapse, more than 6 months from completion of treatment in BCP-ALL. Contemporary chemotherapy combined with HSCT in MRD poor responders to induction treatment is able to cure 70% of children<sup><a href="#ref-74">74</a></sup>. In this group, deletion of <i>IKZF1</i> transcription factor and alteration of <i>TP53</i> identify patients with significantly inferior outcome<sup><a href="#ref-75">75</a></sup>. The outcome of early BM relapses of BCP-ALL (during treatment or less than 6 months from the completion of treatment) and all BM relapses of T-ALL is worse. HSCT is indicated in all of these patients achieving remission. Only one-third of them are cured<sup><a href="#ref-76">76</a></sup>. Deletion of <i>IKZF1</i> is strongly predictive of a second relapse after HSCT<sup><a href="#ref-75">75</a></sup>. <i>IKZF1</i> and <i>TP53</i> represent relevant prognostic factors that should be considered in the assessment of children with relapsed ALL. The outcome of isolated and combined extramedullary relapses depends on the interval between diagnosis and relapse. HSCT may improve the outcome of those with highest risk.</p><p class="" id=d30476e646>The results of allogeneic HSCT are steadily improving. There is no difference in outcome between HSCT from matched sibling donors (MSDs) and unrelated main histocompatibility antigen-identical 9–10/10 volunteers (matched unrelated donor [MUD]). Transplant-related mortality is now below 10% in MSD and 20% in MUD HSCT. The likelihood of being cured by HSCT performed in second remission is about 60%<sup><a href="#ref-31">31</a></sup>. Standard conditioning regimens include total body irradiation, which is associated with significant risk of secondary cancer. Substituting chemotherapy for total body irradiation is currently being evaluated by a randomized study.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e656>Immunotherapy</h2><p class="" id=d30476e659>The intensity of current front-line therapy has reached its threshold. Further intensification is not realistic. The majority of children with early BM relapse currently have little chance to be cured. There is growing evidence that targeted treatment and immunotherapy have the potential to improve the outcome of childhood ALL with reduced toxicity. A novel method of cellular therapy is based on the use of adoptively transferred T lymphocytes which were modified <i>in vitro</i> prior to transfer to express an artificial signaling molecule designated chimeric antigen receptor (CAR). The CAR redirects the specificity of the modified T lymphocytes to surface antigens expressed by malignant cells. The most successful example of CAR-based immunotherapy is the treatment of BCP-ALL by targeting of the surface antigen CD19. In a pilot study, CR was achieved in 90% of 30 children and adults with highly refractory disease<sup><a href="#ref-77">77</a></sup>. CAR cells can cross the blood-brain barrier and eliminate leukemic cells in the cerebrospinal fluid. CAR cells of the third generation are able to engraft and persist for at least several months<sup><a href="#ref-78">78</a></sup>. The most common acute toxicity of CAR T cells is cytokine release syndrome. A wide variety of cytokines, including interleukin-6, interferon-gamma, and tumor necrosis factor, are elevated in the serum of patients experiencing fever, tachycardia, hypotension, and other toxicities. Higher disease burden predicts more toxicity. The interleukin-6 receptor antagonist tocilizumab is widely used for toxicity following CAR infusion<sup><a href="#ref-79">79</a></sup>. Randomized studies are needed to demonstrate whether they will be able to substitute HSCT.</p><p class="" id=d30476e677>Blinatumomab, a bi-specific anti-CD19/CD3 chimeric antibody, draws malignant B cells in close proximity to CD3-positive T cells. Activated T cells effectively induce serial target cell killing. In current clinical trials, blinatumomab is administered over a 28-day continuous infusion, followed by a 14-day rest period. In a phase I/II study of blinatumomab in children, objective responses were noted in 43% patients, including negative MRD in 39% of patients. Optimal placement of immunotherapy with blinatumomab or other conventional immunomodulating approaches or both has yet to be determined<sup><a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>.</p><p class="" id=d30476e687>The anti-CD22 immunoconjugate inotuzumab ozogamicin is an antibody-drug conjugate, consisting of humanized anti-CD22 monoclonal antibody joined to the cytotoxic agent calicheamicin by a non-immunogenic linker. After inotuzumab calicheamicin binds to CD22, rapid internalization of the conjugated calicheamicin occurs, targeting tubulin and inducing DNA breakage, apoptosis, and cell death. The response rate in adults with refractory/relapsed ALL is 80%, and clinical studies in children were launched recently<sup><a href="#ref-82">82</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e697>Conclusions</h2><p class="" id=d30476e700>Despite advances in targeted therapy approaches, conventional chemotherapy is unlikely to be replaced and this is because of its impressive cure rate in ALL. The task in coming years will be to compare immunotherapy with standard chemotherapy on a randomized basis in frontline treatment and in the treatment of first relapse. The goals are to also cure those children in whom combined chemotherapy fails and to reduce the toxicity that is responsible for reducing the quality of life for those who are cured.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d30476e707>Abbreviations</h2><p class="" id=d30476e710>ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Münster (study group); BM, bone marrow; CAR, chimeric antigen receptor; CNS, central nervous system; CR, complete remission; CRT, cranial radiotherapy; DS, Down syndrome; DS-ALL; acute lymphoblastic leukemia in children with Down syndrome; EFS; event-free survival; ETP, early T-cell precursor; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; HD, high-dose; HSCT, hematopoietic stem cell transplantation; IgH/TCR, heavy immunoglobulin/T-cell receptor; MRD, minimal residual disease; MSD, matched sibling donor; MTX, methotrexate; MUD, matched unrelated donor; OS, overall survival; Ph<sup>+</sup> ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; TKI, tyrosine kinase inhibitor; TRM, treatment-related mortality.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d30476e1 class=n-a></a><h2 class=main-title id=d30743>Competing interests</h2><p class=metadata-entry><a name=d30476e90 class=n-a></a><p id=d30476e92> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d30476e1 class=n-a></a><h2 class=main-title id=d30745>Grant information</h2><p>Supported by the project (Ministry of Health) for conceptual development of research organization 0006420 (University Hospital Motol, Prague, Czech Republic).</p></div><div class=back-section><a name=d30476e720 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d31030>References</h2><div class="section ref-list"><a name=d30476e720 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d30476e727 class=n-a></a>Hunger SP, Lu X, Devidas M, <i> et al.</i>: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. <i>J Clin Oncol.</i> 2012; <b>30</b>(14): 1663–9. <a target=xrefwindow id=d30476e738 href="http://www.ncbi.nlm.nih.gov/pubmed/22412151">PubMed Abstract </a> | <a target=xrefwindow id=d30476e741 href="http://dx.doi.org/10.1200/JCO.2011.37.8018">Publisher Full Text </a> | <a target=xrefwindow id=d30476e745 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3383113">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d30476e754 class=n-a></a>Pui CH, Pei D, Campana D, <i> et al.</i>: A revised definition for cure of childhood acute lymphoblastic leukemia. <i>Leukemia.</i> 2014; <b>28</b>(12): 2336–43. <a target=xrefwindow id=d30476e765 href="http://www.ncbi.nlm.nih.gov/pubmed/24781017">PubMed Abstract </a> | <a target=xrefwindow id=d30476e768 href="http://dx.doi.org/10.1038/leu.2014.142">Publisher Full Text </a> | <a target=xrefwindow id=d30476e772 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4214904">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d30476e781 class=n-a></a>Stary J, Zimmermann M, Campbell M, <i> et al.</i>: Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. <i>J Clin Oncol.</i> 2014; <b>32</b>(3): 174–84. <a target=xrefwindow id=d30476e792 href="http://www.ncbi.nlm.nih.gov/pubmed/24344215">PubMed Abstract </a> | <a target=xrefwindow id=d30476e795 href="http://dx.doi.org/10.1200/JCO.2013.48.6522">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d30476e804 class=n-a></a>van Dongen JJ, van der Velden VH, Brüggemann M, <i> et al.</i>: Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. <i>Blood.</i> 2015; <b>125</b>(26): 3996–4009. <a target=xrefwindow id=d30476e815 href="http://www.ncbi.nlm.nih.gov/pubmed/25999452">PubMed Abstract </a> | <a target=xrefwindow id=d30476e818 href="http://dx.doi.org/10.1182/blood-2015-03-580027">Publisher Full Text </a> | <a target=xrefwindow id=d30476e822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4490298">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d30476e831 class=n-a></a>Flohr T, Schrauder A, Cazzaniga G, <i> et al.</i>: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. <i>Leukemia.</i> 2008; <b>22</b>(4): 771–82. <a target=xrefwindow id=d30476e842 href="http://www.ncbi.nlm.nih.gov/pubmed/18239620">PubMed Abstract </a> | <a target=xrefwindow id=d30476e845 href="http://dx.doi.org/10.1038/leu.2008.5">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d30476e855 class=n-a></a>Borowitz MJ, Wood BL, Devidas M, <i> et al.</i>: Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood.</i> 2015; <b>126</b>(8): 964–71. <a target=xrefwindow id=d30476e866 href="http://www.ncbi.nlm.nih.gov/pubmed/26124497">PubMed Abstract </a> | <a target=xrefwindow id=d30476e869 href="http://dx.doi.org/10.1182/blood-2015-03-633685">Publisher Full Text </a> | <a target=xrefwindow id=d30476e873 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4543229">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d30476e882 class=n-a></a>Nachman JB, Sather HN, Sensel MG, <i> et al.</i>: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. <i>N Engl J Med.</i> 1998; <b>338</b>(23): 1663–71. <a target=xrefwindow id=d30476e893 href="http://www.ncbi.nlm.nih.gov/pubmed/9614257">PubMed Abstract </a> | <a target=xrefwindow id=d30476e896 href="http://dx.doi.org/10.1056/NEJM199806043382304">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d30476e905 class=n-a></a>Seibel NL, Steinherz PG, Sather HN, <i> et al.</i>: Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood.</i> 2008; <b>111</b>(5): 2548–55. <a target=xrefwindow id=d30476e916 href="http://www.ncbi.nlm.nih.gov/pubmed/18039957">PubMed Abstract </a> | <a target=xrefwindow id=d30476e919 href="http://dx.doi.org/10.1182/blood-2007-02-070342">Publisher Full Text </a> | <a target=xrefwindow id=d30476e923 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2254538">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d30476e932 class=n-a></a>Lange BJ, Bostrom BC, Cherlow JM, <i> et al.</i>: Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. <i>Blood.</i> 2002; <b>99</b>(3): 825–33. <a target=xrefwindow id=d30476e943 href="http://www.ncbi.nlm.nih.gov/pubmed/11806983">PubMed Abstract </a> | <a target=xrefwindow id=d30476e946 href="http://dx.doi.org/10.1182/blood.V99.3.825">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d30476e955 class=n-a></a>Vora A, Goulden N, Mitchell C, <i> et al.</i>: Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(8): 809–18. <a target=xrefwindow id=d30476e966 href="http://www.ncbi.nlm.nih.gov/pubmed/24924991">PubMed Abstract </a> | <a target=xrefwindow id=d30476e969 href="http://dx.doi.org/10.1016/S1470-2045(14)70243-8">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d30476e978 class=n-a></a>Matloub Y, Bostrom BC, Hunger SP, <i> et al.</i>: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood.</i> 2011; <b>118</b>(2): 243–51. <a target=xrefwindow id=d30476e989 href="http://www.ncbi.nlm.nih.gov/pubmed/21562038">PubMed Abstract </a> | <a target=xrefwindow id=d30476e992 href="http://dx.doi.org/10.1182/blood-2010-12-322909">Publisher Full Text </a> | <a target=xrefwindow id=d30476e996 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3138679">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d30476e1006 class=n-a></a>Vora A, Goulden N, Wade R, <i> et al.</i>: Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(3): 199–209. <a target=xrefwindow id=d30476e1017 href="http://www.ncbi.nlm.nih.gov/pubmed/23395119">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1020 href="http://dx.doi.org/10.1016/S1470-2045(12)70600-9">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/3070956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1029 class=n-a></a>Conter V, Bartram CR, Valsecchi MG, <i> et al.</i>: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. <i>Blood.</i> 2010; <b>115</b>(16): 3206–14. <a target=xrefwindow id=d30476e1040 href="http://www.ncbi.nlm.nih.gov/pubmed/20154213">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1043 href="http://dx.doi.org/10.1182/blood-2009-10-248146">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/3070956">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/12599960"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1056 class=n-a></a>Schrappe M, Valsecchi MG, Bartram CR, <i> et al.</i>: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. <i>Blood.</i> 2011; <b>118</b>(8): 2077–84. <a target=xrefwindow id=d30476e1067 href="http://www.ncbi.nlm.nih.gov/pubmed/21719599">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1070 href="http://dx.doi.org/10.1182/blood-2011-03-338707">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/12599960">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d30476e1083 class=n-a></a>Wood BL, Winter SS, Dunsmore KP, <i> et al.</i>: T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434. <i>Blood.</i> 2014; <b>124</b>(21): 1. <a target=xrefwindow id=d30476e1094 href="http://www.bloodjournal.org/content/124/21/1">Reference Source</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d30476e1103 class=n-a></a>Coustan-Smith E, Mullighan CG, Onciu M, <i> et al.</i>: Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. <i>Lancet Oncol.</i> 2009; <b>10</b>(2): 147–56. <a target=xrefwindow id=d30476e1114 href="http://www.ncbi.nlm.nih.gov/pubmed/19147408">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1117 href="http://dx.doi.org/10.1016/S1470-2045(08)70314-0">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1121 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2840241">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726145512"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1130 class=n-a></a>Conter V, Valsecchi MG, Buldini B, <i> et al.</i>: Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. <i>Lancet Haematol.</i> 2016; <b>3</b>(2): e80–6. <a target=xrefwindow id=d30476e1141 href="http://www.ncbi.nlm.nih.gov/pubmed/26853647">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1144 href="http://dx.doi.org/10.1016/S2352-3026(15)00254-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726145512">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726155612"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1158 class=n-a></a>Möricke A, Zimmermann M, Valsecchi MG, <i> et al.</i>: Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. <i>Blood.</i> 2016; <b>127</b>(17): 2101–12. <a target=xrefwindow id=d30476e1169 href="http://www.ncbi.nlm.nih.gov/pubmed/26888258">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1172 href="http://dx.doi.org/10.1182/blood-2015-09-670729">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726155612">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726056554"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1185 class=n-a></a>Jackson RK, Irving JA, Veal GJ: Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia. <i>Br J Haematol.</i> 2016; <b>173</b>(1): 13–24. <a target=xrefwindow id=d30476e1193 href="http://www.ncbi.nlm.nih.gov/pubmed/26729065">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1196 href="http://dx.doi.org/10.1111/bjh.13924">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726056554">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726313869"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1209 class=n-a></a>Larsen EC, Devidas M, Chen S, <i> et al.</i>: Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>J Clin Oncol.</i> 2016; <b>34</b>(20): 2380–8. <a target=xrefwindow id=d30476e1220 href="http://www.ncbi.nlm.nih.gov/pubmed/27114587">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1223 href="http://dx.doi.org/10.1200/JCO.2015.62.4544">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4981974">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726313869">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d30476e1240 class=n-a></a>Pieters R, Hunger SP, Boos J, <i> et al.</i>: <span style="font-variant: small-caps">l</span>-asparaginase treatment in acute lymphoblastic leukemia: a focus on <i>Erwinia</i> asparaginase. <i>Cancer.</i> 2011; <b>117</b>(2): 238–49. <a target=xrefwindow id=d30476e1258 href="http://www.ncbi.nlm.nih.gov/pubmed/20824725">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1261 href="http://dx.doi.org/10.1002/cncr.25489">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3000881">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718246819"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1273 class=n-a></a>Tong WH, Pieters R, Kaspers GJ, <i> et al.</i>: A prospective study on drug monitoring of PEGasparaginase and <i>Erwinia</i> asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. <i>Blood.</i> 2014; <b>123</b>(13): 2026–33. <a target=xrefwindow id=d30476e1287 href="http://www.ncbi.nlm.nih.gov/pubmed/24449211">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1291 href="http://dx.doi.org/10.1182/blood-2013-10-534347">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1294 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3968389">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718246819">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725924636"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1307 class=n-a></a>Place AE, Stevenson KE, Vrooman LM, <i> et al.</i>: Intravenous pegylated asparaginase versus intramuscular native <i>Escherichia coli</i> <span style="font-variant: small-caps">l</span>-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(16): 1677–90. <a target=xrefwindow id=d30476e1325 href="http://www.ncbi.nlm.nih.gov/pubmed/26549586">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1328 href="http://dx.doi.org/10.1016/S1470-2045(15)00363-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725924636">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d30476e1342 class=n-a></a>Salzer WL, Asselin B, Supko JG, <i> et al.</i>: <i>Erwinia</i> asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. <i>Blood.</i> 2013; <b>122</b>(4): 507–14. <a target=xrefwindow id=d30476e1356 href="http://www.ncbi.nlm.nih.gov/pubmed/23741010">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1360 href="http://dx.doi.org/10.1182/blood-2013-01-480822">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1363 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3724190">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d30476e1372 class=n-a></a>Schmiegelow K, Levinsen MF, Attarbaschi A, <i> et al.</i>: Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 2013; <b>31</b>(19): 2469–76. <a target=xrefwindow id=d30476e1383 href="http://www.ncbi.nlm.nih.gov/pubmed/23690411">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1386 href="http://dx.doi.org/10.1200/JCO.2012.47.0500">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1390 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3807139">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725430339"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1399 class=n-a></a>Cheung YT, Krull KR: Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. <i>Neurosci Biobehav Rev.</i> 2015; <b>53</b>: 108–20. <a target=xrefwindow id=d30476e1407 href="http://www.ncbi.nlm.nih.gov/pubmed/25857254">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1410 href="http://dx.doi.org/10.1016/j.neubiorev.2015.03.016">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1413 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4425605">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725430339">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d30476e1426 class=n-a></a>Richards S, Pui CH, Gayon P, <i> et al.</i>: Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(2): 185–95. <a target=xrefwindow id=d30476e1437 href="http://www.ncbi.nlm.nih.gov/pubmed/22693038">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1440 href="http://dx.doi.org/10.1002/pbc.24228">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1444 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3461084">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1161525"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1453 class=n-a></a>Pui CH, Campana D, Pei D, <i> et al.</i>: Treating childhood acute lymphoblastic leukemia without cranial irradiation. <i>N Engl J Med.</i> 2009; <b>360</b>(26): 2730–41. <a target=xrefwindow id=d30476e1464 href="http://www.ncbi.nlm.nih.gov/pubmed/19553647">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1467 href="http://dx.doi.org/10.1056/NEJMoa0900386">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1471 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2754320">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1161525">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726070164"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1484 class=n-a></a>Vora A, Andreano A, Pui CH, <i> et al.</i>: Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. <i>J Clin Oncol.</i> 2016; <b>34</b>(9): 919–26. <a target=xrefwindow id=d30476e1495 href="http://www.ncbi.nlm.nih.gov/pubmed/26755523">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1498 href="http://dx.doi.org/10.1200/JCO.2015.64.2850">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1502 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4871998">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726070164">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726132009"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1516 class=n-a></a>Jacola LM, Krull KR, Pui CH, <i> et al.</i>: Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol. <i>J Clin Oncol.</i> 2016; <b>34</b>(11): 1239–47. <a target=xrefwindow id=d30476e1527 href="http://www.ncbi.nlm.nih.gov/pubmed/26858334">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1530 href="http://dx.doi.org/10.1200/JCO.2015.64.3205">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872325">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726132009">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725383833"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1547 class=n-a></a>Peters C, Schrappe M, von Stackelberg A, <i> et al.</i>: Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(11): 1265–74. <a target=xrefwindow id=d30476e1558 href="http://www.ncbi.nlm.nih.gov/pubmed/25753432">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1561 href="http://dx.doi.org/10.1200/JCO.2014.58.9747">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725383833">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d30476e1574 class=n-a></a>Schrappe M, Hunger SP, Pui CH, <i> et al.</i>: Outcomes after induction failure in childhood acute lymphoblastic leukemia. <i>N Engl J Med.</i> 2012; <b>366</b>(15): 1371–81. <a target=xrefwindow id=d30476e1585 href="http://www.ncbi.nlm.nih.gov/pubmed/22494120">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1588 href="http://dx.doi.org/10.1056/NEJMoa1110169">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1592 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3374496">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718386892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1601 class=n-a></a>Bhatia S, Landier W, Hageman L, <i> et al.</i>: 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood.</i> 2014; <b>124</b>(15): 2345–53. <a target=xrefwindow id=d30476e1612 href="http://www.ncbi.nlm.nih.gov/pubmed/24829202">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1615 href="http://dx.doi.org/10.1182/blood-2014-01-552166">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1619 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4192748">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718386892">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d30476e1632 class=n-a></a>Eden T, Pieters R, Richards S, <i> et al.</i>: Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. <i>Br J Haematol.</i> 2010; <b>149</b>(5): 722–33. <a target=xrefwindow id=d30476e1643 href="http://www.ncbi.nlm.nih.gov/pubmed/20331462">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1646 href="http://dx.doi.org/10.1111/j.1365-2141.2010.08148.x">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d30476e1655 class=n-a></a>Conter V, Valsecchi MG, Silvestri D, <i> et al.</i>: Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. <i>Lancet.</i> 2007; <b>369</b>(9556): 123–31. <a target=xrefwindow id=d30476e1666 href="http://www.ncbi.nlm.nih.gov/pubmed/17223475">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1669 href="http://dx.doi.org/10.1016/S0140-6736(07)60073-7">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725540965"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1679 class=n-a></a>Clappier E, Grardel N, Bakkus M, <i> et al.</i>: IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951. <i>Leukemia.</i> 2015; <b>29</b>(11): 2154–61. <a target=xrefwindow id=d30476e1690 href="http://www.ncbi.nlm.nih.gov/pubmed/26050650">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1693 href="http://dx.doi.org/10.1038/leu.2015.134">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725540965">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d30476e1706 class=n-a></a>O'Connor D, Bate J, Wade R, <i> et al.</i>: Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. <i>Blood.</i> 2014; <b>124</b>(7): 1056–61. <a target=xrefwindow id=d30476e1717 href="http://www.ncbi.nlm.nih.gov/pubmed/24904116">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1720 href="http://dx.doi.org/10.1182/blood-2014-03-560847">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d30476e1729 class=n-a></a>Schmiegelow K, Attarbaschi A, Barzilai S, <i> et al.</i>: Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. <i>Lancet Oncol.</i> 2016; <b>17</b>(6): e231–9. <a target=xrefwindow id=d30476e1740 href="http://www.ncbi.nlm.nih.gov/pubmed/27299279">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1743 href="http://dx.doi.org/10.1016/S1470-2045(16)30035-3">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718220091"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1752 class=n-a></a>Navarrete M, Rossi E, Brivio E, <i> et al.</i>: Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(5): 803–9. <a target=xrefwindow id=d30476e1763 href="http://www.ncbi.nlm.nih.gov/pubmed/24376115">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1766 href="http://dx.doi.org/10.1002/pbc.24911">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718220091">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726889687"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1779 class=n-a></a>Jabeen K, Ashraf MS, Iftikhar S, <i> et al.</i>: The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC). <i>J Pediatr Hematol Oncol.</i> 2016; <b>38</b>(8): 587–596. <a target=xrefwindow id=d30476e1790 href="http://www.ncbi.nlm.nih.gov/pubmed/27467375">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1793 href="http://dx.doi.org/10.1097/MPH.0000000000000653">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726889687">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d30476e1806 class=n-a></a>Zaliova M, Hovorkova L, Vaskova M, <i> et al.</i>: Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index &lt; 1.16. <i>Genes Chromosomes Cancer.</i> 2016; <b>55</b>(9): 727–37. <a target=xrefwindow id=d30476e1817 href="http://www.ncbi.nlm.nih.gov/pubmed/27163296">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1820 href="http://dx.doi.org/10.1002/gcc.22374">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726259281"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1830 class=n-a></a>Moorman AV: New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. <i>Haematologica.</i> 2016; <b>101</b>(4): 407–16. <a target=xrefwindow id=d30476e1838 href="http://www.ncbi.nlm.nih.gov/pubmed/27033238">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1841 href="http://dx.doi.org/10.3324/haematol.2015.141101">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1844 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5004393">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726259281">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725925831"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1857 class=n-a></a>Mullighan CG, Jeha S, Pei D, <i> et al.</i>: Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. <i>Blood.</i> 2015; <b>126</b>(26): 2896–9. <a target=xrefwindow id=d30476e1868 href="http://www.ncbi.nlm.nih.gov/pubmed/26527677">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1871 href="http://dx.doi.org/10.1182/blood-2015-09-671131">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1875 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4692147">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725925831">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1146974"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1888 class=n-a></a>Mullighan CG, Su X, Zhang J, <i> et al.</i>: Deletion of <i>IKZF1</i> and prognosis in acute lymphoblastic leukemia. <i>N Engl J Med.</i> 2009; <b>360</b>(5): 470–80. <a target=xrefwindow id=d30476e1902 href="http://www.ncbi.nlm.nih.gov/pubmed/19129520">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1906 href="http://dx.doi.org/10.1056/NEJMoa0808253">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1909 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2674612">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1146974">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d30476e1922 class=n-a></a>Den Boer ML, van Slegtenhorst M, De Menezes RX, <i> et al.</i>: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. <i>Lancet Oncol.</i> 2009; <b>10</b>(2): 125–34. <a target=xrefwindow id=d30476e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/19138562">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1936 href="http://dx.doi.org/10.1016/S1470-2045(08)70339-5">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1940 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2707020">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718501948"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1949 class=n-a></a>Roberts KG, Pei D, Campana D, <i> et al.</i>: Outcomes of children with <i>BCR-ABL1</i>–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. <i>J Clin Oncol.</i> 2014; <b>32</b>(27): 3012–20. <a target=xrefwindow id=d30476e1963 href="http://www.ncbi.nlm.nih.gov/pubmed/25049327">PubMed Abstract </a> | <a target=xrefwindow id=d30476e1967 href="http://dx.doi.org/10.1200/JCO.2014.55.4105">Publisher Full Text </a> | <a target=xrefwindow id=d30476e1970 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4162497">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718501948">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726144733"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e1983 class=n-a></a>Schwab C, Ryan SL, Chilton L, <i> et al.</i>: <i>EBF1-PDGFRB</i> fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. <i>Blood.</i> 2016; <b>127</b>(18): 2214–8. <a target=xrefwindow id=d30476e1997 href="http://www.ncbi.nlm.nih.gov/pubmed/26872634">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2001 href="http://dx.doi.org/10.1182/blood-2015-09-670166">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726144733">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718775441"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2015 class=n-a></a>Roberts KG, Li Y, Payne-Turner D, <i> et al.</i>: Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <i>N Engl J Med.</i> 2014; <b>371</b>(11): 1005–15. <a target=xrefwindow id=d30476e2026 href="http://www.ncbi.nlm.nih.gov/pubmed/25207766">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2029 href="http://dx.doi.org/10.1056/NEJMoa1403088">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2033 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4191900">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718775441">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717954876"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2046 class=n-a></a>Biondi A, Schrappe M, De Lorenzo P, <i> et al.</i>: Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. <i>Lancet Oncol.</i> 2012; <b>13</b>(9): 936–45. <a target=xrefwindow id=d30476e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/22898679">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2060 href="http://dx.doi.org/10.1016/S1470-2045(12)70377-7">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2064 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3431502">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717954876">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718243456"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2077 class=n-a></a>Schultz KR, Carroll A, Heerema NA, <i> et al.</i>: Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. <i>Leukemia.</i> 2014; <b>28</b>(7): 1467–71. <a target=xrefwindow id=d30476e2088 href="http://www.ncbi.nlm.nih.gov/pubmed/24441288">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2091 href="http://dx.doi.org/10.1038/leu.2014.30">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4282929">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718243456">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d30476e2108 class=n-a></a>Zaliova M, Fronkova E, Krejcikova K, <i> et al.</i>: Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. <i>Leukemia.</i> 2009; <b>23</b>(5): 944–51. <a target=xrefwindow id=d30476e2119 href="http://www.ncbi.nlm.nih.gov/pubmed/19158828">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2122 href="http://dx.doi.org/10.1038/leu.2008.386">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d30476e2131 class=n-a></a>Bleckmann K, Schrappe M: Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. <i>Br J Haematol.</i> 2016; <b>172</b>(6): 855–69. <a target=xrefwindow id=d30476e2139 href="http://www.ncbi.nlm.nih.gov/pubmed/26773444">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2142 href="http://dx.doi.org/10.1111/bjh.13896">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/10112956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2151 class=n-a></a>Pui CH, Pei D, Campana D, <i> et al.</i>: Improved prognosis for older adolescents with acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 2011; <b>29</b>(4): 386–91. <a target=xrefwindow id=d30476e2162 href="http://www.ncbi.nlm.nih.gov/pubmed/21172890">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2165 href="http://dx.doi.org/10.1200/JCO.2010.32.0325">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3058285">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/10112956">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d30476e2183 class=n-a></a>Pichler H, Reismüller B, Steiner M, <i> et al.</i>: The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. <i>Br J Haematol.</i> 2013; <b>161</b>(4): 556–65. <a target=xrefwindow id=d30476e2194 href="http://www.ncbi.nlm.nih.gov/pubmed/23480776">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2197 href="http://dx.doi.org/10.1111/bjh.12292">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725850708"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2206 class=n-a></a>Sanjuan-Pla A, Bueno C, Prieto C, <i> et al.</i>: Revisiting the biology of infant t(4;11)/MLL-AF4<sup>+</sup> B-cell acute lymphoblastic leukemia. <i>Blood.</i> 2015; <b>126</b>(25): 2676–85. <a target=xrefwindow id=d30476e2220 href="http://www.ncbi.nlm.nih.gov/pubmed/26463423">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2224 href="http://dx.doi.org/10.1182/blood-2015-09-667378">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4683329">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725850708">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718174783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2240 class=n-a></a>Buitenkamp TD, Izraeli S, Zimmermann M, <i> et al.</i>: Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. <i>Blood.</i> 2014; <b>123</b>(1): 70–7. <a target=xrefwindow id=d30476e2251 href="http://www.ncbi.nlm.nih.gov/pubmed/24222333">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2254 href="http://dx.doi.org/10.1182/blood-2013-06-509463">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2258 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3879907">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718174783">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d30476e2271 class=n-a></a>Arber DA, Orazi A, Hasserjian R, <i> et al.</i>: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood.</i> 2016; <b>127</b>(20): 2391–405. <a target=xrefwindow id=d30476e2282 href="http://www.ncbi.nlm.nih.gov/pubmed/27069254">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2285 href="http://dx.doi.org/10.1182/blood-2016-03-643544">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d30476e2294 class=n-a></a>Bene MC, Bernier M, Casasnovas RO, <i> et al.</i>: The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). <i>Blood.</i> 1998; <b>92</b>(2): 596–9. <a target=xrefwindow id=d30476e2305 href="http://www.ncbi.nlm.nih.gov/pubmed/9657760">PubMed Abstract </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d30476e2314 class=n-a></a>Bene MC, Porwit A: Acute leukemias of ambiguous lineage. <i>Semin Diagn Pathol.</i> 2012; <b>29</b>(1): 12–8. <a target=xrefwindow id=d30476e2322 href="http://www.ncbi.nlm.nih.gov/pubmed/22372202">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2325 href="http://dx.doi.org/10.1053/j.semdp.2011.08.004">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d30476e2335 class=n-a></a>Mejstrikova E, Volejnikova J, Fronkova E, <i> et al.</i>: Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. <i>Haematologica.</i> 2010; <b>95</b>(6): 928–35. <a target=xrefwindow id=d30476e2346 href="http://www.ncbi.nlm.nih.gov/pubmed/20145275">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2349 href="http://dx.doi.org/10.3324/haematol.2009.014506">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2878790">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d30476e2362 class=n-a></a>Kotrova M, Musilova A, Stuchly J, <i> et al.</i>: Distinct bilineal leukemia immunophenotypes are not genetically determined. <i>Blood.</i> 2016; pii: blood-2016-07-725861. <a target=xrefwindow id=d30476e2370 href="http://www.ncbi.nlm.nih.gov/pubmed/27625363">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2373 href="http://dx.doi.org/10.1182/blood-2016-07-725861">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d30476e2382 class=n-a></a>Rossi JG, Bernasconi AR, Alonso CN, <i> et al.</i>: Lineage switch in childhood acute leukemia: an unusual event with poor outcome. <i>Am J Hematol.</i> 2012; <b>87</b>(9): 890–7. <a target=xrefwindow id=d30476e2393 href="http://www.ncbi.nlm.nih.gov/pubmed/22685031">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2396 href="http://dx.doi.org/10.1002/ajh.23266">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d30476e2405 class=n-a></a>Slamova L, Starkova J, Fronkova E, <i> et al.</i>: CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. <i>Leukemia.</i> 2014; <b>28</b>(3): 609–20. <a target=xrefwindow id=d30476e2416 href="http://www.ncbi.nlm.nih.gov/pubmed/24270736">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2419 href="http://dx.doi.org/10.1038/leu.2013.354">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718118822"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2428 class=n-a></a>Clappier E, Auclerc MF, Rapion J, <i> et al.</i>: An intragenic <i>ERG</i> deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent <i>IKZF1</i> deletions. <i>Leukemia.</i> 2014; <b>28</b>(1): 70–7. <a target=xrefwindow id=d30476e2446 href="http://www.ncbi.nlm.nih.gov/pubmed/24064621">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2449 href="http://dx.doi.org/10.1038/leu.2013.277">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718118822">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d30476e2462 class=n-a></a>Hrusak O, Luks A, Janotova I, <i> et al.</i>: Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. <i>Blood.</i> 2015; <b>126</b>(23): 252. <a target=xrefwindow id=d30476e2473 href="http://www.bloodjournal.org/content/126/23/252?sso-checked=true">Reference Source</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725939482"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2483 class=n-a></a>Irving JA: Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia. <i>Br J Haematol.</i> 2016; <b>172</b>(5): 655–66. <a target=xrefwindow id=d30476e2491 href="http://www.ncbi.nlm.nih.gov/pubmed/26568036">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2494 href="http://dx.doi.org/10.1111/bjh.13852">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725939482">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d30476e2507 class=n-a></a>Locatelli F, Schrappe M, Bernardo ME, <i> et al.</i>: How I treat relapsed childhood acute lymphoblastic leukemia. <i>Blood.</i> 2012; <b>120</b>(14): 2807–16. <a target=xrefwindow id=d30476e2518 href="http://www.ncbi.nlm.nih.gov/pubmed/22896001">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2521 href="http://dx.doi.org/10.1182/blood-2012-02-265884">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d30476e2530 class=n-a></a>Mullighan CG: Mutant <i>PRPS1</i>: a new therapeutic target in relapsed acute lymphoblastic leukemia. <i>Nat Med.</i> 2015; <b>21</b>(6): 553–4. <a target=xrefwindow id=d30476e2541 href="http://www.ncbi.nlm.nih.gov/pubmed/26046573">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2544 href="http://dx.doi.org/10.1038/nm.3876">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725395576"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2553 class=n-a></a>Ma X, Edmonson M, Yergeau D, <i> et al.</i>: Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. <i>Nat Commun.</i> 2015; <b>6</b>: 6604. <a target=xrefwindow id=d30476e2564 href="http://www.ncbi.nlm.nih.gov/pubmed/25790293">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2567 href="http://dx.doi.org/10.1038/ncomms7604">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2571 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4377644">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725395576">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717983108"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2584 class=n-a></a>Meyer JA, Wang J, Hogan LE, <i> et al.</i>: Relapse-specific mutations in <i>NT5C2</i> in childhood acute lymphoblastic leukemia. <i>Nat Genet.</i> 2013; <b>45</b>(3): 290–4. <a target=xrefwindow id=d30476e2598 href="http://www.ncbi.nlm.nih.gov/pubmed/23377183">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2602 href="http://dx.doi.org/10.1038/ng.2558">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2605 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3681285">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717983108">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725483919"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2618 class=n-a></a>Li B, Li H, Bai Y, <i> et al.</i>: Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. <i>Nat Med.</i> 2015; <b>21</b>(6): 563–71. <a target=xrefwindow id=d30476e2629 href="http://www.ncbi.nlm.nih.gov/pubmed/25962120">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2632 href="http://dx.doi.org/10.1038/nm.3840">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4670083">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725483919">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/9343957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2650 class=n-a></a>Mullighan CG, Zhang J, Kasper LH, <i> et al.</i>: <i>CREBBP</i> mutations in relapsed acute lymphoblastic leukaemia. <i>Nature.</i> 2011; <b>471</b>(7337): 235–9. <a target=xrefwindow id=d30476e2664 href="http://www.ncbi.nlm.nih.gov/pubmed/21390130">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2668 href="http://dx.doi.org/10.1038/nature09727">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2671 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3076610">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/9343957">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/7823960"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2684 class=n-a></a>Parker C, Waters R, Leighton C, <i> et al.</i>: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. <i>Lancet.</i> 2010; <b>376</b>(9757): 2009–17. <a target=xrefwindow id=d30476e2695 href="http://www.ncbi.nlm.nih.gov/pubmed/21131038">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2698 href="http://dx.doi.org/10.1016/S0140-6736(10)62002-8">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2702 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3010035">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/7823960">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d30476e2715 class=n-a></a>Eckert C, Henze G, Seeger K, <i> et al.</i>: Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. <i>J Clin Oncol.</i> 2013; <b>31</b>(21): 2736–42. <a target=xrefwindow id=d30476e2726 href="http://www.ncbi.nlm.nih.gov/pubmed/23775972">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2729 href="http://dx.doi.org/10.1200/JCO.2012.48.5680">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d30476e2738 class=n-a></a>Krentz S, Hof J, Mendioroz A, <i> et al.</i>: Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. <i>Leukemia.</i> 2013; <b>27</b>(2): 295–304. <a target=xrefwindow id=d30476e2749 href="http://www.ncbi.nlm.nih.gov/pubmed/22699455">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2752 href="http://dx.doi.org/10.1038/leu.2012.155">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725382591"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2761 class=n-a></a>Eckert C, Hagedorn N, Sramkova L, <i> et al.</i>: Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. <i>Leukemia.</i> 2015; <b>29</b>(8): 1648–55. <a target=xrefwindow id=d30476e2772 href="http://www.ncbi.nlm.nih.gov/pubmed/25748682">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2775 href="http://dx.doi.org/10.1038/leu.2015.59">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725382591">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/722007528"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2788 class=n-a></a>Maude SL, Frey N, Shaw PA, <i> et al.</i>: Chimeric antigen receptor T cells for sustained remissions in leukemia. <i>N Engl J Med.</i> 2014; <b>371</b>(16): 1507–17. <a target=xrefwindow id=d30476e2799 href="http://www.ncbi.nlm.nih.gov/pubmed/25317870">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2802 href="http://dx.doi.org/10.1056/NEJMoa1407222">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4267531">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/722007528">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d30476e2820 class=n-a></a>Maus MV, Grupp SA, Porter DL, <i> et al.</i>: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. <i>Blood.</i> 2014; <b>123</b>(17): 2625–35. <a target=xrefwindow id=d30476e2831 href="http://www.ncbi.nlm.nih.gov/pubmed/24578504">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2834 href="http://dx.doi.org/10.1182/blood-2013-11-492231">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3999751">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726372756"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2847 class=n-a></a>Brudno JN, Kochenderfer JN: Toxicities of chimeric antigen receptor T cells: recognition and management. <i>Blood.</i> 2016; <b>127</b>(26): 3321–30. <a target=xrefwindow id=d30476e2855 href="http://www.ncbi.nlm.nih.gov/pubmed/27207799">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2858 href="http://dx.doi.org/10.1182/blood-2016-04-703751">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4929924">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726372756">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d30476e2874 class=n-a></a>Gore L, Locatelli F, Zugmaier G, <i> et al.</i>: Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia [abstract]. <i>Blood.</i> 2014; <b>124</b>: 3703. <a target=xrefwindow id=d30476e2885 href="http://www.bloodjournal.org/content/124/21/3703?sso-checked=true">Reference Source</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718349106"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2894 class=n-a></a>Schlegel P, Lang P, Zugmaier G, <i> et al.</i>: Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. <i>Haematologica.</i> 2014; <b>99</b>(7): 1212–9. <a target=xrefwindow id=d30476e2905 href="http://www.ncbi.nlm.nih.gov/pubmed/24727818">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2908 href="http://dx.doi.org/10.3324/haematol.2013.100073">Publisher Full Text </a> | <a target=xrefwindow id=d30476e2912 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4077083">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718349106">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726419915"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d30476e2925 class=n-a></a>Kantarjian HM, DeAngelo DJ, Stelljes M, <i> et al.</i>: Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>N Engl J Med.</i> 2016; <b>375</b>(8): 740–53. <a target=xrefwindow id=d30476e2936 href="http://www.ncbi.nlm.nih.gov/pubmed/27292104">PubMed Abstract </a> | <a target=xrefwindow id=d30476e2939 href="http://dx.doi.org/10.1056/NEJMoa1509277">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726419915">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Nov 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2635/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2635/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2635/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 04 Nov 2016, 5:2635 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9548.1">https://doi.org/10.12688/f1000research.9548.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Starý J and Hrušák O. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10285 data-id=9548 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9548.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2635/v1/pdf?article_uuid=faf62d79-ce36-4f23-9cf8-1a8a3144742d" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9548.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Starý J and Hrušák O. Recent advances in the management of pediatric acute lymphoblastic leukemia [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2635 (<a href="https://doi.org/10.12688/f1000research.9548.1" target=_blank>https://doi.org/10.12688/f1000research.9548.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9548 id=mobile-track-article-signin-9548 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9548?target=/articles/5-2635/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10285 /> <input name=articleId type=hidden value=9548 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Valentino Conter</strong>, University of Milano-Biocca, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stephen Sallan</strong>, Dana-Farber Cancer Institute, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Nov 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2635/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2635/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=17900-17299></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=2998-17298></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2635/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>04 Nov 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Valentino Conter</strong>, University of Milano-Biocca, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stephen Sallan</strong>, Dana-Farber Cancer Institute, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2635/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2635/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the management of pediatric...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2635/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2635/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2635/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Starý J and Hrušák O');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2635/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2635",
            templates : {
                twitter : "Recent advances in the management of pediatric acute lymphoblastic.... Starý J and Hrušák O, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2635/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the management of pediatric acute lymphoblastic leukemia", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the management of pediatric acute lymphoblastic leukemia", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9548/10285")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10285");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "17298": 0,
                           "17299": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "536868c3-d84f-43ea-87fe-e54e4bcda4dd";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2635.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2635.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2635.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2635.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2635.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>